Advertisement

International Journal of Hematology

, Volume 99, Issue 6, pp 737–742 | Cite as

Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma

  • Shogo Kumagai
  • Masaharu Tashima
  • Jun Fujikawa
  • Makoto Iwasaki
  • Yoshihiro Iwamoto
  • Yuki Sueki
  • Akiko Fukunaga
  • Soshi Yanagita
  • Momoko Nishikori
  • Akifumi Takaori-Kondo
  • Nobuyoshi ArimaEmail author
Original Article

Abstract

The prognosis of follicular lymphoma (FL) is significantly associated with host immunity and tumor microenvironment. Lymphopenia has been identified as a negative prognostic factor for FL. The association between monocytosis and progression-free survival (PFS) in FL remains controversial. It is unknown whether the ratio of peripheral blood absolute lymphocyte count to absolute monocyte count (ALC/AMC) at diagnosis is associated with FL prognosis. We studied 99 consecutive patients with FL who were treated with rituximab-containing chemotherapy at Kitano Hospital or Kyoto University Hospital between 2000 and 2012. We analyzed individual variables associated with the ALC/AMC ratio before treatment, as well as known prognostic factors of FL, and found that an ALC/AMC ratio of 4.7 was the best cut-off value for PFS. Kaplan–Meier analysis showed that a decreased ALC/AMC ratio was associated with inferior PFS (P = 0.022). Multivariate analysis showed that a decreased ALC/AMC ratio was a significant poor prognostic factor independent of other variables (hazard ratio, 2.714; 95 % confidence interval, 1.060–6.948; P = 0.037). The ALC/AMC ratio before treatment may be a significant prognostic factor predicting PFS of FL.

Keywords

Follicular lymphoma Absolute lymphocyte count to absolute monocyte count ratio Progression-free survival 

Notes

Acknowledgments

No financial support for this study was provided. The authors would like to thank Dr. Norimitsu Kadowaki, Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, for his administrative assistance.

Conflict of interest

The authors report no potential conflicts of interest.

Supplementary material

12185_2014_1576_MOESM1_ESM.eps (400 kb)
Supplementary material 1 (EPS 400 kb)

References

  1. 1.
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification project. Blood 1997; 89:3909-18.Google Scholar
  2. 2.
    Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2. J Clin Oncol. 2009;27:4555–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–69.PubMedCrossRefGoogle Scholar
  5. 5.
    Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica. 2012;97:262–9.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin’s lymphoma: correlation with tumor-associated macrophages. Oncologist. 2012;17:871–80.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2012;157:321–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  10. 10.
    Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. 2010;51:199–212.PubMedCrossRefGoogle Scholar
  11. 11.
    Solal-Céligny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol. 2010;92(2):246–54.PubMedCrossRefGoogle Scholar
  12. 12.
    Parker D, Alison DL, Barnard DL, Child JA, Dovey G, Farish J, et al. Prognosis in low grade non-Hodgkin’s lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level. Hematol Oncol. 1994;12:15–27.PubMedCrossRefGoogle Scholar
  13. 13.
    Decaudin D, Des Guetz G, Mathiot C, Dumont J, Hubert P, Vincent-Salomon A, et al. Absolute lymphocyte count as a predictive factor for response to monoclonal anti-CD20 antibody therapy. Ann Oncol. 2003;14:171–2.PubMedCrossRefGoogle Scholar
  14. 14.
    Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383–91.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol. 2007;137:409–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Shafer D, Smith MR, Borghaei H, Millenson MM, Li T, Litwin S, Anad R, Al-Saleem T. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. Leuk Res. 2013;37:1213–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, et al. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma. 2012;53:575–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14 + HLA-DR (low)/-monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011;117:872–81.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Watanabe R, Tomita N, Kishimoto K, Koyama S, Ogusa E, Ishii Y, et al. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Res. 2013;37:1208–12.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2014

Authors and Affiliations

  • Shogo Kumagai
    • 1
  • Masaharu Tashima
    • 2
  • Jun Fujikawa
    • 3
  • Makoto Iwasaki
    • 1
  • Yoshihiro Iwamoto
    • 1
  • Yuki Sueki
    • 1
  • Akiko Fukunaga
    • 1
  • Soshi Yanagita
    • 1
  • Momoko Nishikori
    • 2
  • Akifumi Takaori-Kondo
    • 2
  • Nobuyoshi Arima
    • 1
    Email author
  1. 1.Department of Hematology, Tazuke Kofukai Medical Research InstituteKitano HospitalOsakaJapan
  2. 2.Department of Hematology and Oncology, Graduate School of MedicineKyoto UniversityKyotoJapan
  3. 3.Department of Laboratory Medicine, Tazuke Kofukai Medical Research InstituteKitano HospitalOsakaJapan

Personalised recommendations